Speciality: Oncology
Description:
Welcome to this insightful video featuring Dr. Viraj Nevrekar, where he delves into the molecular differences between two critical EGFR mutations—Exon 19 deletion and Exon 21 L858R. These mutations are pivotal in non-small cell lung cancer (NSCLC) and influence treatment responses, making their understanding essential for clinicians and researchers. Dr. Nevrekar expertly breaks down the structural and functional disparities between these mutations, explaining how Exon 19 deletions lead to ligand-independent activation of EGFR, while L858R alters the kinase domain’s affinity for ATP. His analysis provides a clear perspective on why these differences matter in therapeutic decision-making.
In the second segment, Dr. Nevrekar explores the clinical implications of these EGFR mutations, highlighting how Exon 19 deletions often correlate with better responses to tyrosine kinase inhibitors (TKIs) compared to L858R. He discusses recent studies that reveal differences in downstream signaling pathways, tumor microenvironments, and resistance mechanisms between the two variants. By presenting real-world data and case studies, he underscores the importance of personalized medicine in NSCLC, ensuring viewers grasp the practical relevance of these molecular distinctions in improving patient outcomes.
As the discussion concludes, Dr. Nevrekar emphasizes the ongoing research into novel therapeutic strategies targeting these mutations, including next-generation TKIs and combination therapies. His engaging presentation not only educates but also inspires further exploration into precision oncology. Don’t miss this comprehensive breakdown—watch the full video to gain valuable insights and stay tuned for more enlightening discussions from Dr. Nevrekar on emerging trends in molecular oncology!
See More Webinars @ Hidoc Webinars
1.
Three out of ten breast cancers detected between screenings, study finds
2.
Second Malignancy Risk With CAR T-Cell Therapy on Par With Other Treatments
3.
Where Did This Very Painful Gluteal Mass Come From?
4.
As compared to proton therapy, proton therapy is very effective in treating esophageal cancer.
5.
Rucaparib Delays Next Lines of Therapy in Ovarian Cancer
1.
Exploring The Science Of Hematopoietic Stem Cell Transplantation: What You Need To Know
2.
Optimizing Melanoma Treatment: Strategies in Diagnosis, Clinical Research, and Physician Training
3.
Unleashing the Oncolytic Arsenal: Talimogene Laherparepvec Monotherapy – A Targeted Cancer Immunotherapy Treatment
4.
Clonal Hematopoiesis Dynamics and Future Hematologic Outcomes
5.
Understanding Mesenteric Masses: Symptoms, Diagnosis, and Treatment Options
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
Incidence of Lung Cancer- An Overview to Understand ALK Rearranged NSCLC
2.
Treatment Sequencing Strategies in ALK + NSCLC Patients with CNS Diseases - Part II
3.
Evidence-Based Oncology
4.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part IV
5.
Preventing Immune Effector Cell-Associated Neurotoxicity Through Early Neurovascular Biomarker Surveillance
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation